Literature DB >> 25975838

Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.

Chang-Xin Shi1, Klaus Martin Kortüm1, Yuan Xiao Zhu1, Patrick Jedlowski1, Laura Bruins1, Esteban Braggio1, A Keith Stewart2.   

Abstract

Entities:  

Keywords:  IKZF1 depletion; IMiDs; myeloma

Mesh：

Substances：

Year:  2015        PMID： 25975838      PMCID： PMC5004433          DOI： 10.3324/haematol.2015.124297

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

2.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Scott Van Wier; Xiu-Bao Chang; Chad C Bjorklund; Rafael Fonseca; P Leif Bergsagel; Robert Z Orlowski; A Keith Stewart
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

3.  Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

Authors:  M Wang; K Delasalle; S Giralt; R Alexanian
Journal:  Hematology       Date:  2010-04       Impact factor: 2.269

4.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

5.  Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Authors:  Ruben Niesvizky; Thomas G Martin; William I Bensinger; Melissa Alsina; David S Siegel; Lori A Kunkel; Alvin F Wong; Susan Lee; Robert Z Orlowski; Michael Wang
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

6.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

7.  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Authors:  Paul G Richardson; Wanling Xie; Sundar Jagannath; Andrzej Jakubowiak; Sagar Lonial; Noopur S Raje; Melissa Alsina; Irene M Ghobrial; Robert L Schlossman; Nikhil C Munshi; Amitabha Mazumder; David H Vesole; Jonathan L Kaufman; Kathleen Colson; Mary McKenney; Laura E Lunde; John Feather; Michelle E Maglio; Diane Warren; Dixil Francis; Teru Hideshima; Robert Knight; Dixie-Lee Esseltine; Constantine S Mitsiades; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-15       Impact factor: 22.113

8.  Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Authors:  Philip P Chamberlain; Antonia Lopez-Girona; Karen Miller; Gilles Carmel; Barbra Pagarigan; Barbara Chie-Leon; Emily Rychak; Laura G Corral; Yan J Ren; Maria Wang; Mariko Riley; Silvia L Delker; Takumi Ito; Hideki Ando; Tomoyuki Mori; Yoshinori Hirano; Hiroshi Handa; Toshio Hakoshima; Thomas O Daniel; Brian E Cathers
Journal:  Nat Struct Mol Biol       Date:  2014-08-10       Impact factor: 15.369

Review 9.  Carfilzomib.

Authors:  K Martin Kortuem; A Keith Stewart
Journal:  Blood       Date:  2013-02-07       Impact factor: 22.113

10.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728
View more
  16 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

2.  Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.

Authors:  Enrica Borsi; Marina Martello; Barbara Santacroce; Elena Zamagni; Paola Tacchetti; Lucia Pantani; Katia Mancuso; Serena Rocchi; Michele Cavo; Carolina Terragna
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

Review 3.  The novel mechanism of lenalidomide activity.

Authors:  Emma C Fink; Benjamin L Ebert
Journal:  Blood       Date:  2015-10-05       Impact factor: 22.113

4.  Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.

Authors:  Taro Tochigi; Takatoshi Aoki; Yoshikane Kikushige; Tomohiko Kamimura; Yoshikiyo Ito; Takahiro Shima; Takuji Yamauchi; Yasuo Mori; Goichi Yoshimoto; Kenjiro Kamezaki; Koji Kato; Katsuto Takenaka; Hiromi Iwasaki; Koichi Akashi; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2016-11-21       Impact factor: 2.490

5.  Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.

Authors:  Shiori Kinoshita; Masaki Ri; Takashi Kanamori; Sho Aoki; Takashi Yoshida; Tomoko Narita; Haruhito Totani; Asahi Ito; Shigeru Kusumoto; Takashi Ishida; Hirokazu Komatsu; Shinsuke Iida
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

6.  Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.

Authors:  Zachary J Walker; Michael J VanWyngarden; Brett M Stevens; Diana Abbott; Andrew Hammes; Christophe Langouët-Astrie; Clayton A Smith; Brent E Palmer; Peter A Forsberg; Tomer M Mark; Craig T Jordan; Daniel W Sherbenou
Journal:  Blood Adv       Date:  2020-04-28

7.  Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.

Authors:  Sinto Sebastian; Yuan X Zhu; Esteban Braggio; Chang-Xin Shi; Sonali C Panchabhai; Scott A Van Wier; Greg J Ahmann; Marta Chesi; P Leif Bergsagel; A Keith Stewart; Rafael Fonseca
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

8.  Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Authors:  Richard J Jones; Tawin Iempridee; Xiaobin Wang; Hans C Lee; Janet E Mertz; Shannon C Kenney; Heather C Lin; Veerabhadran Baladandayuthapani; Christopher W Dawson; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2016-06-13       Impact factor: 12.531

9.  Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.

Authors:  Yayoi Matsumura-Kimoto; Junya Kuroda; Hitomi Kaneko; Yuri Kamitsuji; Shin-Ichi Fuchida; Aya Nakaya; Hirohiko Shibayama; Nobuhiko Uoshima; Isao Yokota; Hitoji Uchiyama; Hideo Yagi; Satoru Kosugi; Toshimitsu Matsui; Jun Ishikawa; Mitsuhiro Matsuda; Kensuke Ohta; Masato Iida; Hirokazu Tanaka; Masayuki Kobayashi; Katsuya Wada; Chihiro Shimazaki; Shosaku Nomura; Kazunori Imada; Masayuki Hino; Itaru Matsumura; Yuzuru Kanakura; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

10.  Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells.

Authors:  Saravanan Ganesan; Hamenth Kumar Palani; Nithya Balasundaram; Sachin David; Anup J Devasia; Biju George; Vikram Mathews
Journal:  Mol Cancer Res       Date:  2020-01-08       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.